{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:23Z","timestamp":1789398143274,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00575-5","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:26:21Z","timestamp":1787196381000},"page":"383-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Follow-Up Therapeutic Drug Monitoring and Vancomycin-Induced Nephrotoxicity: A Claims Database Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-4333","authenticated-orcid":false,"given":"Tomoyuki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-613X","authenticated-orcid":false,"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-4642","authenticated-orcid":false,"given":"Taku","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Neo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"575_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030489","volume":"14","author":"K Matsumoto","year":"2022","unstructured":"Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, et al. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022;14:489. https:\/\/doi.org\/10.3390\/pharmaceutics14030489.","journal-title":"Pharmaceutics"},{"key":"575_CR2","first-page":"1","volume":"70","author":"Y Takesue","year":"2022","unstructured":"Takesue Y, Kimura T, Matsumoto K, Mayumi T, Hamada Y, Kimura T, et al. [Clinical practice guidelines for therapeutic drug monitoring of antimicrobial drugs 2022] (in Japanese). Jpn J Chemother. 2022;70:1\u201372.","journal-title":"Jpn J Chemother."},{"key":"575_CR3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71:1361\u20134. https:\/\/doi.org\/10.1093\/cid\/ciaa303.","journal-title":"Clin Infect Dis"},{"key":"575_CR4","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2215\/CJN.05920616","volume":"11","author":"A Sinha Ray","year":"2016","unstructured":"Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11:2132\u201340. https:\/\/doi.org\/10.2215\/CJN.05920616.","journal-title":"Clin J Am Soc Nephrol"},{"key":"575_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077169","volume":"8","author":"ZK Ye","year":"2013","unstructured":"Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS ONE. 2013;8:e77169. https:\/\/doi.org\/10.1371\/journal.pone.0077169.","journal-title":"PLoS ONE"},{"key":"575_CR6","unstructured":"Ministry of Health, Labour and Welfare (Japan). https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411_00027.html. Accessed 15 Nov 2022."},{"key":"575_CR7","unstructured":"Japan Medical Data Center. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. Accessed 5 Oct 2022."},{"key":"575_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jgf2.367","volume":"21","author":"K Nagai","year":"2020","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims databases sourced from medical institutions. J Gen Fam Med. 2020;21:211\u20138. https:\/\/doi.org\/10.1002\/jgf2.367.","journal-title":"J Gen Fam Med"},{"key":"575_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82\u201398. https:\/\/doi.org\/10.2146\/ajhp080434.","journal-title":"Am J Health Syst Pharm"},{"key":"575_CR10","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1111\/bcp.15252","volume":"88","author":"S Imai","year":"2022","unstructured":"Imai S, Kadomura S, Miyai T, Kashiwagi H, Sato Y, Sugawara M, et al. Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity. Br J Clin Pharmacol. 2022;88:3241\u201355. https:\/\/doi.org\/10.1111\/bcp.15252.","journal-title":"Br J Clin Pharmacol"},{"key":"575_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"575_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"EJ Filippone","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102:459\u201369. https:\/\/doi.org\/10.1002\/cpt.726.","journal-title":"Clin Pharmacol Ther"},{"key":"575_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05858-6","volume":"21","author":"M Tsutsuura","year":"2021","unstructured":"Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis. 2021;21:153. https:\/\/doi.org\/10.1186\/s12879-021-05858-6.","journal-title":"BMC Infect Dis"},{"key":"575_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/2042018816638223","volume":"7","author":"O Bamgbola","year":"2016","unstructured":"Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7:136\u201347. https:\/\/doi.org\/10.1177\/2042018816638223.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"575_CR15","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/ajhp\/zxz120","volume":"76","author":"WC Rutter","year":"2019","unstructured":"Rutter WC, Hall RG, Burgess DS. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin\u2013tazobactam and vancomycin. Am J Health Syst Pharm. 2019;76:1211\u20137. https:\/\/doi.org\/10.1093\/ajhp\/zxz120.","journal-title":"Am J Health Syst Pharm"},{"key":"575_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jiac.2022.05.007","volume":"28","author":"S Ito","year":"2022","unstructured":"Ito S, Goto R, Inose R, Kusama Y, Ono A, Koizumi R, et al. A study of trends and factors associated with therapeutic drug monitoring (TDM) implementation for arbekacin treatment using a large Japanese medical claims database. J Infect Chemother. 2022;28:1266\u201372. https:\/\/doi.org\/10.1016\/j.jiac.2022.05.007.","journal-title":"J Infect Chemother"},{"key":"575_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106202","volume":"89","author":"S Mitsuboshi","year":"2024","unstructured":"Mitsuboshi S, Imai S, Kizaki H, Hori S. Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database. J Infect. 2024;89:106202. https:\/\/doi.org\/10.1016\/j.jinf.2024.106202.","journal-title":"J Infect"},{"key":"575_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"key":"575_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jgar.2021.07.018","volume":"27","author":"N Hashimoto","year":"2021","unstructured":"Hashimoto N, Kimura T, Hamada Y, Niwa T, Hanai Y, Chuma M, et al. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. J Glob Antimicrob Resist. 2021;27:12\u20139. https:\/\/doi.org\/10.1016\/j.jgar.2021.07.018.","journal-title":"J Glob Antimicrob Resist"},{"key":"575_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/jac\/dkn080","volume":"62","author":"PR Ingram","year":"2008","unstructured":"Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008;62:168\u201371. https:\/\/doi.org\/10.1093\/jac\/dkn080.","journal-title":"J Antimicrob Chemother"},{"key":"575_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10156-013-0551-7","volume":"19","author":"Y Takahashi","year":"2013","unstructured":"Takahashi Y, Takesue Y, Takubo S, Ishihara M, Nakajima K, Tsuchida T, et al. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin. J Infect Chemother. 2013;19:709\u201316. https:\/\/doi.org\/10.1007\/s10156-013-0551-7.","journal-title":"J Infect Chemother"},{"key":"575_CR22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/cts.13626","volume":"16","author":"K Oda","year":"2023","unstructured":"Oda K, Yamada T, Matsumoto K, Hanai Y, Ueda T, Samura M, et al. Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: a simulation study. Clin Transl Sci. 2023;16:2265\u201375. https:\/\/doi.org\/10.1111\/cts.13626.","journal-title":"Clin Transl Sci"},{"key":"575_CR23","first-page":"175","volume":"65","author":"K Matsumoto","year":"2017","unstructured":"Matsumoto K, Isoda R, Kuroda Y, Yokoyama Y, Kizu J. National survey of therapeutic drug monitoring (TDM) of antimicrobial drugs\u2014Comparison with the TDM guidelines for antimicrobial drugs (in Japanese). Jpn J Chemother. 2017;65:175\u201382.","journal-title":"Jpn J Chemother."},{"key":"575_CR24","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/jac\/dkad333","volume":"78","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Niwa T, Ono Y, Yamada S, Niwa K, Yasue M, et al. Comparison of the incidence of vancomycin-associated nephrotoxicity following the change from trough-guided dosing to AUC-guided dosing using trough-only data. J Antimicrob Chemother. 2023;78:2933\u20137. https:\/\/doi.org\/10.1093\/jac\/dkad333.","journal-title":"J Antimicrob Chemother"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00575-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:36Z","timestamp":1789394556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00575-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00575-5","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"23 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Osaka Medical and Pharmaceutical University (protocol number: 2022\u2013105) and performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for obtaining informed consent was waived because the study was a retrospective analysis of routinely collected data.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not contain any identifying information or images of individual participants.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data employed in our research were obtained through a contractual agreement with the Japan Medical Data Center (JMDC). Consequently, these data are not publicly available. Researchers interested in utilizing the same dataset may acquire it from JMDC. For any inquiries or to establish contact with JMDC, please refer to the website at\n                      \n                      .","order":5,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All statistical analyses were performed using R version 4.5.2 with standard statistical packages. No custom code was developed for this study.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors meet the ICMJE authorship criteria. TY was responsible for organization and coordination of the study. TY and SI designed the study. TY and SI analysed the data. TY, KM, and TO curated the data. AU and MNi managed this study, and MNe supervised the study. All authors contributed to the writing of the final manuscript and the management and conduct of the study. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}